Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ConfometRx

- PMLiVE

UCB boosted by core medicines growth

Firm’s new chief executive 'excited' by his company’s next batch of medicines

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

UCB CEO elected to the Ministerial Industry Strategy Group

Jean-Christophe Tellier assumed the role of CEO on January 1

- PMLiVE

UCB submits brivaracetam for use in epilepsy

Files drug in both the US and EU

- PMLiVE

New UCB CEO Jean-Christophe Tellier expands his executive team

Hands new roles to Emmanuel Caeymaex, Bharat Tewarie and Jeff Wren

- PMLiVE

UCB moves Cimzia into phase III trials for psoriasis

Firm collaborating with Dermira to test efficacy and safety of drug

- PMLiVE

UCB’s $1.53bn generics sale falls through

Advent and Avista Capita back away from bid to acquire Kremers Urban due to unanticipated conflict in timing

- PMLiVE

UCB partners with Daiichi to bring epilepsy drug to Japan

Companies partner on expanding market for Vimpat

EISAI

Eisai establishes neuroscience unit in Belgium and Luxembourg

Follows the company's recent expansion in Australia

- PMLiVE

UCB to sell its US generics business for $1.5bn

Advent International and Avista Capital Partners will take control of Kremers Urban Pharmaceuticals

- PMLiVE

Biogen Idec appoints senior neuroscientists

Christopher Henderson and Richard Ransohoff make the move from academia

Investing in the future of R&D

Roch Doliveux on UCB’s research plans and paying for innovation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links